We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline's new shingles vaccine Shingrix quickly captured the market after winning FDA approval and a preferential recommendation from CDC vaccine advisers, but now strong uptake is leading to supply restrictions.